Janssen Inc. v. Pharmascience Inc., 2023 FC 1464 (Paliperidone*)
Assess.s Morgan - 2023-11-02
Read full decision. Automatically generated summary:
This assessment of costs is related to the Federal Court’s Public Judgment and Reasons (2022 FC 1218) dated August 23, 2022, which stated the following regarding costs (at page 64): 5. Janssen is awarded 25% of reasonable legal fees and 100% of reasonable disbursements, exclusive of any motions for which costs have been fixed including the motion for summary trial in Court file no. T-1441-20, with the following limitations: a) the fees of Dr. Ereshefsky and Dr. Chue are reduced by 25%; b) No fees are awarded for Dr. Gobburu, and costs are awarded to Pharmascience for all reasonable costs thrown away given the last minute failure to call him as a witness at the trial. 6. Within 45 days of receiving this decision, the Parties will endeavour to agree on a reasonable costs quantum in accordance with the foregoing parameters, failing which the costs shall be assessed by an assessment officer in accordance with these reasons and judgment.
Decision relates to:
- T-1422-90 - YOUSSEF HANNA DABLEH v. ONTARIO HYDRO ET AL
- T-1441-20 - JANSSEN INC. ET AL v. PHARMASCIENCE INC.
- T-353-18 - JANSSEN INC. ET AL v. TEVA CANADA LIMITED
- T-455-20 - JANSSEN INC. ET AL. v. PHARMASCIENCE INC.
- T-553-22 - Andrew Girard et al v. The Minister of Transport et al
- T-558-22 - Janssen Inc. et Al. v. Pharmascience Inc.